Anxiety, depression, sexual dysfunction and quality of life in prostate cancer based on stage of the disease

Yıl 2013, , 23 - 7, 01.01.2013

Mehmet Cemal Kaya Yasin Bez Aslan Demir Mahmut Bulut Volkan Topçuoğlu Mehmet Kemal Kuşçu Niyazi Levent Türkeri

https://doi.org/10.5455/jmood.20130215041211

Öz

Background: Prostate cancer is common in men and in many studies quality of life, mental health problems and sexual dysfunction were examined in this population. However, there are relatively few studies examining the impact of the disease according to the stages. In this study we aimed to compare the levels of anxiety, depression, quality of life and sexual dysfunction of the prostate cancer patients according to their stages. Method: 80 patients with prostate cancer who applied to urology outpatient clinic were enrolled to the study. Patients were divided into three groups according to their stages; localized/organ-confined, local spread and metastatic spread. Short Form 36 (SF-36), Hospital Anxiety and Depression Scale (HAD) and the Arizona Sexual Experience Scale (ASEX) were performed. Results: According to the stage of prostate cancer, physical functioning subscale of quality of life was significantly lower in patients with metastatic prostate cancer than in patients with organ-confined prostate cancer (F= 4.53, p= 0.014). There were no associations between anxiety and depression scores and the stage of prostate cancer. Sexual desire was better in organ-confined prostate cancer patients compared to metastatic prostate cancer patients (F= 5.32, p= 0.007). Conclusion: The patients with prostate cancer might have different levels of physical functioning and sexual aversion problems at different stages of the disease. The clinicians should consider these two issues during follow-up of these patients.

Anahtar Kelimeler

prostate cancer, anxiety, depression, sexual dysfunction, quality of life

Prostat kanseri hastalarında hastalık evrelerine göre anksiyete, depresyon, cinsel işlev bozukluğu ve yaşam kalitesi

Öz

Amaç: Erkeklerde sık görülen prostat kanserinde yaşam kalitesi, ruhsal sorunlar ve cinsel işlev bozukluğu birçok çalışmada incelenmiştir. Ancak hastalığın evrelerine göre etkilerinin incelendiği çalışma sayısı oldukça azdır. Biz bu çalışmada prostat kanserli hastaları evrelerine göre sınıflandırarak yaşam kalitesi, cinsel işlev bozukluğu, anksiyete ve depresyon düzeylerini karşılaştırmayı amaçladık. Yöntem: Üroloji kliniğine başvuran 80 prostat kanserli hasta çalışmaya dahil edildi. Hastalar evrelerine göre lokalize/organa sınırlı, lokal yayılımlı ve metastatik olmak üzere üç gruba ayrıldı. Hastalara kısa form 36 (KF-36), hastane anksiyete depresyon ölçeği (HAD) ve Arizona cinsel yaşantılar ölçeği (ACYÖ) uygulandı. Bulgular: Prostat kanseri evresine göre yaşam kalitesinin fiziksel işlevsellik alt boyutu metastatik prostat kanserli hastalarda organa sınırlı hastalara göre anlamlı derecede düşük bulundu (F=4.53, p=0.014). Prostat kanseri evresi ile anksiyete ve depresyon puanları arasında anlamlı ilişki tespit edilmedi. Organa sınırlı hastalığı olanlarda cinsel istek metastatik hastalara göre daha iyi düzeydeydi (F=5.32, p=0.007). Sonuç: Prostat kanseri olan hastalar, hastalığın çeşitli evrelerinde farklı düzeylerde fiziksel işlevsellik ve cinsel isteksizlik sorunları yaşamaktadırlar. Hastaların takibinde klinisyenler bu iki konuyu göz önünde bulundurmalıdır.

Anahtar Kelimeler

prostat kanseri, anksiyete, depresyon, cinsel işlev, yaşam kalitesi

Kaynakça

• Badger TA, Segrin C, Figueredo AJ, Harrington J, Sheppard K, Passalacqua S, et al. Psychosocial interventions to improve quality of life in prostate cancer survivors and their intimate or family partners. Qual Life Res. 2011;20:833-44.
• Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson J-E, Norlén BJ, et al. Quality of Life after Radical Prostatectomy or Watchful Waiting. New England Journal of Medicine. 2002;347:790
• Wei JT, Dunn RL, Sandler HM, McLaughlin PW, Montie JE, Litwin MS, et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J. Clin. Oncol. 2002;20:557-66.
• Onitilo AA, Nietert PJ, Egede LE. Effect of depression on all-cause mortality in adults with cancer and differential effects by cancer site. Gen Hosp Psychiatry. 2006;28:396-402.
• Roth AJ, Kornblith AB, Batel-Copel L, Peabody E, Scher HI, Holland JC. Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study. Cancer. 1998;82:1904-8.
• Pirl WF, Siegel GI, Goode MJ, Smith MR. Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study. Psychooncology. 2002;11:518-23.
• Clark JA, Inui TS, Silliman RA, Bokhour BG, Krasnow SH, Robinson RA, et al. Patients’ perceptions of quality of life after treatment for early prostate cancer. J. Clin. Oncol. 2003;21:3777-84.
• Bacon CG, Giovannucci E, Testa M, Glass TA, Kawachi I. The association of treatment-related symptoms with quality-of-life outcomes for localized prostate carcinoma patients. Cancer. 2002;94:862-71.
• Rosenfeld B, Roth AJ, Gandhi S, Penson D. Differences in healthrelated quality of life of prostate cancer patients based on stage of cancer. Psychooncology. 2004;13:800-7.
• Namiki S, Arai Y. Health-related quality of life in men with localized prostate cancer. Int. J. Urol. 2010;17:125-38.
• Beahrs O H, Henson D, Earl, Hutter RVP, Kennedy BJ. Manual for Staging of Cancer. 4th ed. Philadelphia: American Joint Committee on Cancer. J. B . Lippincott Company, 1992:181-7.
• Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361-70.
• Aydemir Ö. Hastane Anksiyete ve Depresyon Ölçeği Türkçe Formunun Geçerlilik ve Güvenilirlik Çalışması. Turk Psikiyatri Derg. 1997;8:280-7.
• Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-83.
• Koçyiğit H, Aydemir Ö, Ölmez N, Memiş A. Kısa Form 36 (KF-36)’nın Türkçe versiyonunun güvenilirliği ve geçerliliği. İlaç ve Tedavi Dergisi. 1999;12:102-6.
• Aydemir Ö. Konsültasyon-liyezon psikiyatrisinde yaşam kalitesi ölçümü: Kısa Form-36 (SF-36). 3P (Psikiyatri Psikoloji Psikofarmakoloji) Dergisi. 1999;7:14-22.
• McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnight KM, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther. 2000;26:25-40.
• Soykan A. The reliability and validity of Arizona sexual experiences scale in Turkish ESRD patients undergoing hemodialysis. Int. J. Impot. Res. 2004;16:531-4.
• Rossetti SR, Terrone C. Quality of life in prostate cancer patients. Eur. Urol. 1996;30:44-8.
• Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA. 1995;273:129-35.
• Steginga SK, Occhipinti S, Gardiner RAF, Yaxley J, Heathcote P. Prospective study of men’s psychological and decision-related adjustment after treatment for localized prostate cancer. Urology. 2004;63:751-6.
• Bisson JI, Chubb HL, Bennett S, Mason M, Jones D, Kynaston H. The prevalence and predictors of psychological distress in patients with early localized prostate cancer. BJU Int. 2002;90:56-61.
• Balderson N, Towell T. The prevalence and predictors of psychological distress in men with prostate cancer who are seeking support. Br J Health Psychol. 2003;8:125-34.
• Nelson CJ, Choi JM, Mulhall JP, Roth AJ. Determinants of sexual satisfaction in men with prostate cancer. J Sex Med. 2007;4:1422-7. Letts C, Tamlyn K, Byers ES. Exploring the impact of prostate cancer on men’s sexual well-being. J Psychosoc Oncol. 2010;28:490-510.
• Iversen P, Newling D, Kirby R, Eardley I. Sexual function: Quality of life issues in patients with locally advanced non-metastatic prostate cancer. European Urology Supplements. 2002;1:26-32.
• Finney G, Haynes A-M, Cross P, Brenner P, Boyn A, Stricker P. Cross-sectional analysis of sexual function after prostate brachytherapy. Urology. 2005;66:377-81.
• Helgason AR, Adolfsson J, Dickman P, Fredrikson M, Arver S, Steineck G. Waning sexual function--the most important diseasespecific distress for patients with prostate cancer. Br. J. Cancer. 1996;73:1417-21.
• Klotz L. Cancer overdiagnosis and overtreatment. Curr Opin Urol. 2012;22:203-9.